Skadden, A&O Shearman and Davis Polk Advise on Approximately $8.9 Billion Boots Group Acquisition
The Boots Group is being sold to Wittington Investments, the Weston family's Canadian holding company (in partnership with Fairfax Financial Holdings), in a deal valued at approximately $8.9 billion, with Skadden, A&O Shearman and Davis Polk advising on the transaction, according to reporting published on 7 October 2026. The deal comes just over one year after Boots was acquired by Sycamore Partners and the Pessina family, meaning the pharmacy and health-and-beauty retail group is moving swiftly to a new set of private owners. The transaction represents one of the larger private-to-private acquisitions in UK retail in recent years. Boots operates a substantial high-street and online presence across the United Kingdom, with the brand carrying significant consumer recognition. The speed of the re-sale, roughly a year after the prior acquisition, is notable and points to active private capital recycling in the UK consumer sector. Skadden's own deal announcement confirms Wittington is partnering with Fairfax Financial, and that completion is subject to regulatory approvals with closing expected in the first quarter of 2027; further deal-structure and financing detail was not disclosed. What is confirmed is the headline value of approximately $8.9 billion and the involvement of three of the most active transactional firms currently operating in the global M&A market.
Why this matters
A transaction at this scale in UK retail is significant at any moment, but the speed of re-sale signals either a profitable arbitrage by Sycamore Partners and the Pessina family or a strategic repositioning prompted by shifts in the UK consumer and pharmacy market. The involvement of three elite transactional firms (Skadden, A&O Shearman and Davis Polk) on a single deal reflects the complexity and multi-jurisdictional nature of large private equity exits. The deal will likely require CMA merger control assessment given Boots's market share in UK pharmacy and health and beauty.
On the Ground
This matter primarily activates private M&A, leveraged finance (structuring the buyer's acquisition financing), and regulatory clearance (CMA Phase 1 at minimum given Boots's market presence). A&O Shearman's involvement is particularly notable for UK-focused trainees given the firm's deep UK M&A practice. A trainee would assist with drafting conditions precedent (CP) checklists, preparing Companies House filing documents, organising the disclosure letter process, indexing due diligence reports, and coordinating completion logistics.
Interview prep
Question you might get
“What regulatory clearances would a buyer need to obtain to complete a £7bn-plus acquisition of a major UK pharmacy and retail group, and which aspects might attract the closest CMA scrutiny?”
Sign up free to see the full answer
A model answer you can lift into an interview — how to frame this story for a partner.
Sign up freeMy notes
saved